Deal title

Principal company

Partner company

Total projected at signing (US$M)

Most recent event date

FEBRUARY

Albany Molecular Research to provide cGMP manufacturing and analytical support for a complex parenteral drug product

Albany Molecular Research Inc.

Ferrer Internacional SA

Payment
unspecified

2/21/17

Acbel to distribute Antibe's ATB-346 for gastrointestinal ulcer and bleeding associated with NSAIDs in Greece, Romania, Serbia, Bulgaria, Albania, Algeria and Jordan

Antibe Therapeutics Inc.

Laboratories Acbel SA

$1.10

2/24/17

Tersera to commercilaize Astrazeneca's Zoladex in the U.S. and Canada

Astrazeneca plc

Tersera Therapeutics

$320.00

2/20/17

Chinese Peptide and Zhejiang Haiding Pharmaceutical to develop HDP-111001 against undisclosed indication

Chinese Peptide Co.

Zhejiang Haiding Pharmaceutical Co. Ltd.

Unknown

2/22/17

Serum Institute of India to market Cipla's hepatitis B vaccine in India

Cipla Ltd.

Serum Institute of India Ltd.

Payment
unspecified

2/17/17

ANI acquires Holmdel's Innopran XL against hypertension

Holmdel Pharmaceuticals LP

ANI Pharmaceuticals Inc.

$31.00

2/23/17

Inmed and Revive to sign term sheet on discovery and development of cannabinoid therapies for kidney diseases worldwide

Inmed Pharmaceuticals Inc.

Revive Therapeutics Ltd.

Payment
unspecified

2/22/17

Global pharmaceutical company to license Isogenica's llamdA VHH single-domain antibody libraries for the development and commercialization of therapeutic products

Isogenica Ltd.

Undisclosed

Payment
unspecified

2/21/17

Biosense to opt to develop and commercialize Neovacs' IFN alpha kinoid vaccine for lupus and dermatomyositis in China and other selected territories

Neovacs SA

Biosense Global LLC

$69.01

2/21/17

Novozymes and Defensin Therapeutics to develop recombinant human beta-defensin-2 against colitis

Novozymes A/S

Defensin Therapeutics ApS

Payment
unspecified

2/17/17

Finch Therapeutics to license Openbiome's stool banking technology to develop Finch's FIN-403 for recurrent clostridium difficile infection

Openbiome

Finch Therapeutics

Payment
unspecified

2/23/17

Xynomic Pharmaceuticals to develop and commercialize Pharmacyclics' Abexinostat against cancer worldwide

Pharmacyclics Inc.

Xynomic Pharmaceuticals

Payment
unspecified

2/24/17

4P Pharma and Pulsalys to codevelop for the development of Onco-Bcl program against cancer with sublicensing option

Pulsalys Inc.

4P Pharma

Payment
unspecified

2/28/17

Sanofi and Lonza to form joint venture for monoclonal antibody production

Sanofi SA

Lonza Group AG

Unknown

2/27/17

Selexis to develop cell lines using SUREtechnology platform for three Sanofi biologics programs in cancer and infectious disease

Selexis SA

Sanofi SA

Payment
unspecified

2/21/17

Santen and Twoxar to discover new glaucoma candidates using computational drug discovery platform

Twoxar Inc.

Santen Inc.

Payment
unspecified

2/23/17

Sobi to distribute Valeant's Ammonul for urea cycle disorders in Europe, the Middle East and North Africa

Valeant Pharmaceuticals International Inc.

Swedish Orphan Biovitrum AB

Payment
unspecified

2/21/17

Phytecs and Yissum Research to discover endocannabinoid system targeting compounds and to test fluorinated cannabidiol

Yissum Research Development Co.

Phytecs Inc.

Payment
unspecified

2/22/17

Leukocare to provide patented SPS formulation technologies access to Rentschler Biotechnologie

Dr Rentschler Biotechnologie GmbH

Leukocare AG

Payment
unspecified

2/2/17

Edelris to use Keymical Space for identification of lead molecules against Pfizer selected targets

Edelris SAS

Pfizer Inc.

Payment
unspecified

1/31/17

Amag Pharmaceuticals to develop and commercialize Endoceutics' prasterone against dyspareunia, vulva and vaginal atrophy in the U.S.

Endoceutics Inc.

Amag Pharmaceuticals Inc.

$965

2/13/17

Agro-Tek to distribute Engen's Munchies B Gone gum to counteract biological cause of cannabis induced hunger in Canada

Engen Medical Corp.

Agro-Tek Inc.

Payment
unspecified

2/6/17

MARCH

Ajinomoto Althea to provide technology transfer, validation and commercial fill/finish services to Revance's daxibotulinumtoxin A

Ajinomoto Althea Inc.

Revance Therapeutics Inc.

Payment
unspecified

3/14/17

Brill Pharma to distribute Alimera's Iluvien for diabetic macular edema in Spain

Alimera Sciences Inc.

Brill Pharma SL

Payment
unspecified

3/13/17

Horizon Discovery to evaluate impact of Amplycell's BOOST cell line optimization technology on Horizon's parental GS null CHO K1 cell line worldwide

Amplycell SA

Horizon Discovery Group plc

Payment
unspecified

3/8/17

Angsana Molecular & Diagnostics and Ignyta to conduct a STARTRK-2 clinical trial for entrectinib in Asia

Angsana Molecular & Diagnostics Laboratory Pte. Ltd.

Ignyta Inc.

Payment
unspecified

3/3/17

DKSH to distribute APR Applied Pharma Research's diclofenac 50 mg powder for migraine and pain in Asia

APR Applied Pharma Research SA

DKSH Holding Ltd.

Payment
unspecified

3/6/17

Ferring acquires Apricus Biosciences' Vitaros assets outside the U.S.

Apricus Biosciences Inc.

Ferring Pharmaceuticals SA

$13.30

3/8/17

Alexion to use Arbutus' LNP delivery technology in its single messenger RNA product candidate for rare disease programs

Arbutus Biopharma Corp.

Alexion Pharmaceuticals Inc.

$82.50

3/16/17

Argen-X and Staten Biotech to develop ARGX-116 through its Innovative Access Program against dyslipidemia

Argen-X NV

Staten Biotechnology BV

Payment
unspecified

3/6/17

Argen-X and Broteio Pharma to develop therapeutic complement-targeted antibody against autoimmune hemolytic anemia and antibody mediated rejection, with an option

Argen-X NV

Broteio Pharma BV

Payment
unspecified

3/21/17

Circassia to commercialize Astrazeneca's Tudorza and Duaklir for various chronic obstructive pulmonary disease in U.S.

Astrazeneca plc

Circassia Pharmaceuticals plc

$292.50

3/17/17

Biomerieux to develop and market Astute's Nephrocheck test for Vidas, an assay to assess the risk of developing acute kidney injury worldwide

Astute Medical Inc.

Biomerieux SA

Unknown

3/13/17

Roche to supply Tecentriq to evaluate Bavarian's CV-301 and Tecentriq in bladder cancer

Bavarian Nordic A/S

Roche Holding AG

Payment
unspecified

3/10/17

Beigene and GET to establish joint venture to provide funding for research and development of biologic drug candidates in China

Beigene Co. Ltd.

Guangzhou GET Technology Development Co. Ltd.

Unknown

3/7/17

Bergenbio and Merck to conduct phase II clinical studies on BGB-324 in combination with Keytruda against non-small-cell lung cancer and triple-negative breast cancer

Bergenbio AS

Merck & Co. Inc.

Payment
unspecified

3/8/17

Catalyst to use Biocept's target selector platform for LEMS patients in phase III Firdapse trial

Biocept Inc.

Catalyst Pharmaceutical Partners Inc.

Payment
unspecified

3/14/17

MediLoc Laborsysteme to distribute Biolog's product lines in Germany and Austria

Biolog Inc.

Mediloc Laborsysteme GmbH

Payment
unspecified

3/6/17

Mill Creek to distribute Biological Industries' PLTMax Human Platelet Lysate

Biological Industries Co. Ltd.

Mill Creek Life Sciences

Payment
unspecified

3/6/17

Biologics to provide specialty pharmacy services for Novartis' ribociclib against HR+/HER2- advanced breast cancer

Biologics Inc.

Novartis AG

Payment
unspecified

3/17/17

Bioversys and Aptuit to identify and validate new targets and molecules for Gram-negative bacteria

Bioversys AG

Aptuit LLC

Payment
unspecified

3/7/17

Nemus Bioscience to use Catalent's softgel technology for delivery of NB-1222 against chemotherapy-induced nausea and vomiting

Catalent Inc.

Nemus Bioscience Inc.

Payment
unspecified

3/3/17

Bluelink Pharmaceuticals acquires Cerulean Pharma's CRLX-101 and CRLX-301 for cancer

Cerulean Pharma Inc.

Bluelink Pharmaceuticals

$1.50

3/19/17

Provecs to use Cevec's CAPGT technology to develop adenoviral gene therapy vectors for cancer

Cevec Pharmaceuticals GmbH

Provecs Medical GmbH

Payment
unspecified

3/16/17

Medac to use Cevec's CAPGT technology to develop adenoviral gene therapy vectors for cancer

Cevec Pharmaceuticals GmbH

Medac GmbH

Payment
unspecified

3/16/17

Oxford Genetics to distribute CLS Cell Lines Service's cell lines worldwide

CLS Cell Lines Service GmbH

Oxford Genetics Ltd.

Payment
unspecified

3/6/17

Vertex Pharmaceuticals to acquire Concert's CTP-656 against cystic fibrosis

Concert Pharmaceuticals Inc.

Vertex Pharmaceuticals Inc.

$250.00

3/3/17

Neogenomics and Definiens to develop new biomarker assays for clinical trials and clinical testing

Definiens AG

Neogenomics Inc.

Unknown

3/13/17

Diplomat to distribute Lexicon Pharmaceuticals' telotristat against carcinoid syndrome diarrhea

Diplomat Pharmacy Inc.

Lexicon Pharmaceuticals Inc.

Payment
unspecified

3/6/17

China Medical System to commercialize Dr Falk's mesalazine for ulcerative colitis and Crohn's disease in People's Republic of China

Dr. Falk Pharma GmbH

China Medical System Holdings Ltd.

Payment
unspecified

3/16/17

Sandoz to license DSM's IP assets for the manufacture of beta lactam antibiotics worldwide

DSM Sinochem Pharmaceuticals Ltd.

Sandoz Pharmaceuticals Corp.

Payment
unspecified

3/17/17

Duchesnay to develop and commercialize Shionogi's Osphena against dyspareunia in the U.S. and Canada

Duchesnay Inc.

Shionogi Inc.

Payment
unspecified

3/10/17

Allergan to license Editas' 5 genome editing programs including LCA-10 for ocular diseases

Editas Medicine Inc.

Allergan plc

$90.00

3/14/17

Oncbiomune to sign a non-binding term sheet to form a joint venture to develop and commercialize EOC Pharma's products including telatinib in 34 countries of MALA

EOC Pharma Ltd.

Oncbiomune Pharmaceuticals Inc.

Unknown

3/14/17

Fuji Yakuhin and Mochida Pharmaceutical to develop FYU-981 against hyperuricemia

Fuji Yakuhin Co. Ltd.

Mochida Pharmaceutical Co. Ltd.

Payment
unspecified

3/6/17

AGT to conduct phase I clinical studies by combining lentiviral vector technology with Geovax's MVA-VLP HIV vaccine against HIV infection

Geovax Labs Inc.

American Gene Technologies International Inc.

Payment
unspecified

3/14/17

Guangzhou Ruibeisi and Guangzhou Yinheyangguang to investigate a lyophilized, inactived human rabies vaccine produced from Vero cells

Guangzhou Ruibeisi Pharmaceutical Co. Ltd.

Guangzhou Yinheyangguang Biological Products Co. Ltd.

Payment
unspecified

3/6/17

Daiichi Sankyo to develop Heptares' small molecule against G-protein coupled receptors for pain

Heptares Therapeutics Ltd.

Daiichi Sankyo Co. Ltd.

$4.00

3/13/17

Pierre Fabre to distribute Hill Dermaceuticals' Tolak for actinic keratosis in the U.S. and other territories

Hill Dermaceuticals Inc.

Pierre Fabre Dermo-Cosmetique

Payment
unspecified

3/6/17

Pierre Fabre to develop fully human monoclonal antibodies for cancer using H-Immune's IVI technology

H-Immune SAS

Pierre Fabre SA

Payment
unspecified

3/21/17

Immune Therapeutics and Omaera to sign a memorandum of understanding for distribution of Lodonal for HIV infection and immune disorders in Kenya

Immune Therapeutics Inc.

Omaera Pharmaceuticals

Payment
unspecified

3/8/17

Key Capital to distribute Immunitor's immunotherapy products for cancer in Latin America

Immunitor Inc.

Key Capital Corp.

Payment
unspecified

3/7/17

Integral Molecular and Integrated Biotherapeutics to discover and develop virus vaccines against Ebola and Zika virus infection

Integrated Biotherapeutics Inc.

Integral Molecular Inc.

Payment
unspecified

3/2/17

Illumina to comarket Kailos' Targetrich PGxComplete and Kailos Blue research solutions for pharmacogenetics targets

Kailos Genetics Inc.

Illumina Inc.

Payment
unspecified

3/21/17

Kuhnil to distribute Kitov's KIT-302 for pain and hypertension in South Korea

Kitov Pharmaceuticals Ltd.

Kuhnil Pharmaceutical Co. Ltd.

Payment
unspecified

3/8/17

Arix Bioscience and Lead Discovery Center to develop therapeutics for metabolic diseases

Lead Discovery Center GmbH

Arix Bioscience plc

Payment
unspecified

3/20/17

Loxo Oncology and Ventana Medical Systems to develop and commercialize pan-TRK IHC companion diagnostic test to identify tumor types for larotrectinib treatment

Loxo Oncology Inc.

Ventana Medical Systems Inc.

Payment
unspecified

3/20/17

Amring acquires six ANDAs including niche otic and ophthalmic pharmaceuticals from Luitpold Pharmaceuticals and Alphaforce

Luitpold Pharmaceuticals Inc.

Amring Pharmaceuticals

Payment
unspecified

3/1/17

PTC Therapeutics to acquire Marathon Pharmaceuticals' Emflaza against Duchenne muscular dystrophy

Marathon Pharmaceuticals LLC

PTC Therapeutics Inc.

$190.00

3/15/17

Kissei and Maruishi to develop and commercialize MR-13A9 for uremic pruritus in Japan

Maruishi Pharmaceutical Co. Ltd.

Kissei Pharmaceutical Co. Ltd.

Payment
unspecified

3/13/17

Crispr Therapeutics to use Maxcyte's cell engineering platform to develop CRISPR/Cas9-based therapies for hemoglobin diseases and severe-combined immunodeficiency

Maxcyte Inc.

Crispr Therapeutics

Payment
unspecified

3/14/17

Sanofi Pasteur and Medimmune to develop and commercialize MEDI-8897 against respiratory syncytial virus

Medimmune LLC

Sanofi Pasteur Inc.

$647.29

3/3/17

Menarini to develop and commercialize Melinta's delafloxacin against bacterial infections in various countries

Melinta Therapeutics Inc.

The Menarini Group

Payment
unspecified

3/2/17

Mercachem to provide Aicuris lead optimization services for multiple anti-infective targets

Mercachem Holding BV

Aicuris Anti-infective Cures GmbH

Payment
unspecified

3/8/17

Fuji Pharma to enter into a letter of intent with Mithra to develop and commercialize Donesta in Japan and ASEAN

Mithra Pharmaceuticals

Fuji Pharma Co. Ltd.

Payment
unspecified

3/1/17

Bio-Techne to license reagents and media systems from Multiclonal Therapeutics for ground state stem cell technology

Multiclonal Therapeutics Inc.

Bio-Techne Corp.

Payment
unspecified

3/7/17

Nemus to use Nanomerics' MET to develop topical ocular formulation of NB-1111 for glaucoma

Nanomerics Ltd.

Nemus Bioscience Inc.

Payment
unspecified

3/20/17

Neos Therapeutics to license patents rights related to NT-0201 from Shire against attention deficit hyperactivity disorder

Neos Therapeutics Inc.

Shire plc

$1.00

3/6/17

Trovagene to develop and commercialize Nerviano's PCM-075 for acute myeloid leukemia worldwide

Nerviano Medical Sciences Srl

Trovagene Inc.

$2.00

3/15/17

Biocodex to commercialize Neurim's PedPRM for children with sleep disorders in France

Neurim Pharmaceuticals

Laboratoires Biocodex

Payment
unspecified

3/13/17

Servier to develop Neurochlore's bumetanide for autism in Europe

Neurochlore

Servier

Payment
unspecified

3/14/17

Nlife and Wave to develop cell-specific targeting of nucleic acid therapeutics for central nervous system genetic diseases

Nlife Therapeutics SL

Wave Life Sciences Ltd.

Payment
unspecified

3/3/17

Novalix to provide on-site discovery chemistry services for small molecules drug discovery programs for UCB Biopharma

Novalix

UCB Biopharma SPRL

Payment
unspecified

3/7/17

4d Pharma to use Owlstone Medical's biomarker services to discover novel non-invasive biomarkers

Owlstone Medical Ltd.

4d Pharma plc

Payment
unspecified

3/7/17

Mayne to distribute Par Pharmaceutical's fentanyl TDS against pain in the U.S.

Par Pharmaceutical Inc.

Mayne Pharma Group Ltd.

Payment
unspecified

3/9/17

Breath Therapeutics to license Pari Pharma's ciclosporin against bronchiolitis obliterans syndrome

Pari Pharma GmbH

Breath Therapeutics Holding BV

Payment
unspecified

3/20/17

Galapagos and Pharnext to develop new synergistic drug combinations for various indications

Pharnext SAS

Galapagos NV

Payment
unspecified

3/9/17

Poplar Healthcare to offer Roche's cobas HPV test for cervical cancer screening and the cobas EGFR mutation test for non-small-cell lung cancer

Poplar Healthcare

Roche Holding AG

Payment
unspecified

3/13/17

Quintiles to provide development services for Verona's RPL-554 in chronic obstructive pulmonary disease and cystic fibrosis treatment

Quintiles Transnational Corp.

Verona Pharma plc

Payment
unspecified

3/22/17

AMO Pharma and Ranedis to develop RND-001 for various neurological disorders

Ranedis Pharmaceuticals

AMO Pharma Ltd.

Payment
unspecified

3/14/17

R-Health and Bioverativ to conduct research on a coagulation assay using its Rhealth diagnostic platform

R-Health LLC

Bioverativ Inc.

Payment
unspecified

3/7/17

Rubicon and Syngene to develop another application of ARX-050, modified Annexin's ability to target additional tumor cell lines

Rubicon Biotechnology Inc.

Syngene International Ltd.

Payment
unspecified

3/9/17

Sacco to manufacture and supply Optibiotix's cholesterol reducing strain, LPLDL, in Europe

Sacco Srl

Optibiotix Health plc

Payment
unspecified

3/8/17

Chugai to commercialize SBI Pharma's Alaglio for bladder cancer in Japan

SBI Pharmaceuticals

Chugai Pharmaceutical Co. Ltd.

Payment
unspecified

3/13/17

Scohia Pharma to license eight research and development projects from Takeda including TAK-272, TAK-792 and TAK-094

Takeda Pharmaceutical Co. Ltd.

Scohia Pharma Inc.

Payment
unspecified

3/14/17

Oncbiomune to sign term sheet to acquire Teva Pharmaceuticals' norepinefrine generic in Mexico

Teva Pharmaceutical Industries Ltd.

Oncbiomune Pharmaceuticals Inc.

Payment
unspecified

3/20/17

Maruho to develop and commercialize Toray's ROR gamma t inhibitor for autoimmune diseases worldwide

Toray Industries Inc.

Maruho Co. Ltd.

Payment
unspecified

3/14/17

Aequus to enter a binding term sheet to license TRPL's transdermal patch against epilepsy, multiple sclerosis and other neurological disorders worldwide

Transdermal Research Pharm Laboratories LLC

Aequus Pharmaceuticals Inc.

Payment
unspecified

3/2/17

Upsher-Smith to market and distribute undisclosed pharmaceutical company's generic products in the U.S.

Undisclosed

Upsher-Smith Laboratories Inc.

Payment
unspecified

3/17/17

Valeant to develop and commercialize Glycyx's methylnaltrexone bromide containing products for oncology indications outside the U.S. and Canada

Valeant Pharmaceuticals International Inc.

Glycyx Pharmaventures Ltd.

Payment
unspecified

3/15/17

Vedantra and Neon Therapeutics to develop cancer vaccines

Vedantra Pharmaceuticals Inc.

Neon Therapeutics

Payment
unspecified

3/14/17

Namaste Technologies to sign a memorandum of understanding to commercialize Vinergy's cannabidiol extract formulations in the U.S.

Vinergy Resources Ltd.

Namaste Technologies Inc.

Payment
unspecified

3/14/17

X-Chem to discover novel compounds for Astellas' targets against multiple therapeutic areas

X-Chem Inc.

Astellas Pharma Inc.

$116.00

3/20/17

Ono to use X-Chem's DEX platform for small molecules discovery against oncology targets worldwide

X-Chem Inc.

Ono Pharmaceutical Co. Ltd.

Payment
unspecified

3/21/17

Kadimastem to license Yeda's patent related to the method of producing supporting cells in the central nervous system from stem cells

Yeda Research and Development Co. Ltd.

Kadimastem Ltd.

Payment
unspecified

3/16/17

ZS Genetics and Hitachi High Technologies to develop and commercialize ZS Genetics' DNA sequencing platform

ZS Genetics Inc.

Hitachi High Technologies America Inc.

Payment
unspecified

3/8/17

Jiangsu Nhwa to commercialize Zysis' aripiprazole for psychotic disorders in China

Zysis Ltd.

Jiangsu Nhwa Pharmaceutical Group Co. Ltd.

$0.70

3/13/17


Notes

This chart includes only biopharmaceutical deals between companies. Deals with universities and nonprofit entities, as well as mergers and acquisitions, will be highlighted in separate charts. For more information about individual companies and/or products, see Thomson Reuters Cortellis.

 

No Comments